Merck Halts Two Indian Firms From Launching Januvia Copies As It Awaits Crucial Patent Decision
This article was originally published in PharmAsia News
Executive Summary
After halting Aprica in June, Merck has stopped two more Indian companies from a potential launch of sitagliptin copies. But a number of Indian companies are said to be keenly waiting to launch their copies of sitagliptin and a final decision on a patent fight with Glenmark could be the only hurdle holding them back.